147 related articles for article (PubMed ID: 16208003)
41. Investigation of drug resistance against protease, reverse transcriptase, and integrase inhibitors by next-generation sequencing in HIV-positive patients.
Tekin D; Gokengin D; Onay H; Erensoy S; Sertoz R
J Med Virol; 2021 Jun; 93(6):3627-3633. PubMed ID: 33026651
[TBL] [Abstract][Full Text] [Related]
42. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors.
Walter H; Schmidt B; Korn K; Vandamme AM; Harrer T; Uberla K
J Clin Virol; 1999 Jun; 13(1-2):71-80. PubMed ID: 10405894
[TBL] [Abstract][Full Text] [Related]
43. Performance of drug resistance assays in testing HIV-1 non-B subtypes.
Holguín A; Hertogs K; Soriano V
Clin Microbiol Infect; 2003 Apr; 9(4):323-6. PubMed ID: 12667245
[TBL] [Abstract][Full Text] [Related]
44. Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system.
Jármy G; Heinkelein M; Weissbrich B; Jassoy C; Rethwilm A
J Med Virol; 2001 Jul; 64(3):223-31. PubMed ID: 11424108
[TBL] [Abstract][Full Text] [Related]
45. Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants.
Beck IA; Crowell C; Kittoe R; Bredell H; Machaba M; Willamson C; Janssens W; Jallow S; van der Groen G; Shao Y; Jacob M; Samuel NM; de Rivera IL; Ngo-Giang-Huong N; Cassol S; Alemnji G; Frenkel LM
J Acquir Immune Defic Syndr; 2008 Aug; 48(4):418-27. PubMed ID: 18614915
[TBL] [Abstract][Full Text] [Related]
46. HIV type 1 diversity from newly diagnosed patients in Santos metropolitan area/Brazil.
de Sa-Filho DJ; Ambar RF; Duarte NB; Matias RB; Candido V; Gagliani LH; Caseiro MM
AIDS Res Hum Retroviruses; 2009 Sep; 25(9):925-9. PubMed ID: 19689200
[TBL] [Abstract][Full Text] [Related]
47. High prevalence of unique recombinant forms of HIV-1 in Ghana: molecular epidemiology from an antiretroviral resistance study.
Delgado E; Ampofo WK; Sierra M; Torpey K; Pérez-Alvarez L; Bonney EY; Mukadi YD; Lartey M; Nyarko C; Amenyah RN; Thomson M; Nájera R
J Acquir Immune Defic Syndr; 2008 Aug; 48(5):599-606. PubMed ID: 18645511
[TBL] [Abstract][Full Text] [Related]
48. Human immunodeficiency virus drug susceptibility and resistance testing.
Tobin NH; Frenkel LM
Pediatr Infect Dis J; 2002 Jul; 21(7):681-3. PubMed ID: 12237603
[No Abstract] [Full Text] [Related]
49. A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy.
Weber J; Rangel HR; Chakraborty B; Tadele M; Martinez MA; Martinez-Picado J; Marotta ML; Mirza M; Ruiz L; Clotet B; Wrin T; Petropoulos CJ; Quiñones-Mateu ME
J Gen Virol; 2003 Aug; 84(Pt 8):2217-2228. PubMed ID: 12867654
[TBL] [Abstract][Full Text] [Related]
50. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples.
Günthard HF; Wong JK; Ignacio CC; Havlir DV; Richman DD
AIDS Res Hum Retroviruses; 1998 Jul; 14(10):869-76. PubMed ID: 9671215
[TBL] [Abstract][Full Text] [Related]
51. Comparison between sequence analysis and a line probe assay for testing genotypic resistance of human immunodeficiency virus type 1 to antiretroviral drugs.
García-Bujalance S; de Guevara CL; González-García J; Arribas JR; Gutiérrez A
J Clin Microbiol; 2005 Aug; 43(8):4186-8. PubMed ID: 16081972
[TBL] [Abstract][Full Text] [Related]
52. Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility.
Apetrei C; Descamps D; Collin G; Loussert-Ajaka I; Damond F; Duca M; Simon F; Brun-Vézinet F
J Virol; 1998 May; 72(5):3534-8. PubMed ID: 9557632
[TBL] [Abstract][Full Text] [Related]
53. 2019 update of the drug resistance mutations in HIV-1.
Wensing AM; Calvez V; Ceccherini-Silberstein F; Charpentier C; Günthard HF; Paredes R; Shafer RW; Richman DD
Top Antivir Med; 2019 Sep; 27(3):111-121. PubMed ID: 31634862
[TBL] [Abstract][Full Text] [Related]
54. Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma.
Ellis GM; Mahalanabis M; Beck IA; Pepper G; Wright A; Hamilton S; Holte S; Naugler WE; Pawluk DM; Li CC; Frenkel LM
J Clin Microbiol; 2004 Aug; 42(8):3670-4. PubMed ID: 15297515
[TBL] [Abstract][Full Text] [Related]
55. Detection of drug-selected mutations in HIV-1 subtype E reverse transcriptase sequence using the line probe assay.
Lee CC; Thoe SY; Leo YS; Chan KP; Ling AE
AIDS; 2000 May; 14(8):1064-5. PubMed ID: 10853992
[No Abstract] [Full Text] [Related]
56. Review of HIV antiretroviral drug resistance.
Chen TK; Aldrovandi GM
Pediatr Infect Dis J; 2008 Aug; 27(8):749-52. PubMed ID: 18664987
[No Abstract] [Full Text] [Related]
57. One-Step Ligation on RNA Amplification for the Detection of Point Mutations.
Zhang L; Wang J; Coetzer M; Angione S; Kantor R; Tripathi A
J Mol Diagn; 2015 Nov; 17(6):679-88. PubMed ID: 26322949
[TBL] [Abstract][Full Text] [Related]
58. Validation of an oligonucleotide ligation assay for quantification of human immunodeficiency virus type 1 drug-resistant mutants by use of massively parallel sequencing.
Beck IA; Deng W; Payant R; Hall R; Bumgarner RE; Mullins JI; Frenkel LM
J Clin Microbiol; 2014 Jul; 52(7):2320-7. PubMed ID: 24740080
[TBL] [Abstract][Full Text] [Related]
59. Novel enzyme-linked minisequence assay for genotypic analysis of human immunodeficiency virus type 1 drug resistance.
Sugiura W; Shimada K; Matsuda M; Chiba T; Myint L; Okano A; Yamada K
J Clin Microbiol; 2003 Nov; 41(11):4971-9. PubMed ID: 14605126
[TBL] [Abstract][Full Text] [Related]
60. Stability of transmitted drug-resistant HIV-1 species.
Cane PA
Curr Opin Infect Dis; 2005 Dec; 18(6):537-42. PubMed ID: 16258329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
